Article

Interferon-Lambda: A New Addition to an Old Family

Division of Therapeutic Proteins, Center for Drug Evaluation and Research , Food and Drug Administration, Bethesda, Maryland 20892, USA.
Journal of interferon & cytokine research: the official journal of the International Society for Interferon and Cytokine Research (Impact Factor: 2). 08/2010; 30(8):555-64. DOI: 10.1089/jir.2010.0078
Source: PubMed

ABSTRACT

The discovery and initial description of the interferon-lambda (IFN-lambda) family in early 2003 opened an exciting new chapter in the field of IFN research. There are 3 IFN-lambda genes that encode 3 distinct but highly related proteins denoted IFN-lambda1, -lambda2, and -lambda3. These proteins are also known as interleukin-29 (IL-29), IL-28A, and IL-28B, respectively. Collectively, these 3 cytokines comprise the type III subset of IFNs. They are distinct from both type I and type II IFNs for a number of reasons, including the fact that they signal through a heterodimeric receptor complex that is different from the receptors used by type I or type II IFNs. Although type I IFNs (IFN-alpha/beta) and type III IFNs (IFN-lambda) signal via distinct receptor complexes, they activate the same intracellular signaling pathway and many of the same biological activities, including antiviral activity, in a wide variety of target cells. Consistent with their antiviral activity, expression of the IFN-lambda genes and their corresponding proteins is inducible by infection with many types of viruses. Therefore, expression of the type III IFNs (IFN-lambdas) and their primary biological activity are very similar to the type I IFNs. However, unlike IFN-alpha receptors which are broadly expressed on most cell types, including leukocytes, IFN-lambda receptors are largely restricted to cells of epithelial origin. The potential clinical importance of IFN-lambda as a novel antiviral therapeutic agent is already apparent. In addition, preclinical studies by several groups indicate that IFN-lambda may also be useful as a potential therapeutic agent for other clinical indications, including certain types of cancer.

Download full-text

Full-text

Available from: Raymond P Donnelly
  • Source
    • "Viral infection can induce expression of the type III IFNs in a variety of cell types (Kotenko and others 2003; Sheppard and others 2003). These cytokines signal through a heterodimeric receptor complex consisting of IFN-lR1, the ligand-binding chain, and IL-10R2, the accessory chain (Kotenko and others 2003; Sheppard and others 2003; Donnelly and Kotenko 2010). IFNs induce antiviral activity in cells that express the corresponding cell surface receptors, and IFN-lR1 expression is largely restricted to cells of epithelial origin (Sommereyns and others 2008; Mordstein and others 2010). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The expression of a biologically active human IFNλ4 depends on the presence of a frameshift deletion polymorphism within the first exon of the interferon lambda 4 (IFNL4) gene. In this report, we use the lung carcinoma-derived cell line, A549, which is genetically viable to express a functional IFNλ4, to address transcriptional requirements of the IFNL4 gene. We show that the GC-rich DNA-binding transcription factor (TF) specificity protein 1 (Sp1) is recruited to the IFNL4 promoter and has a role in induction of gene expression upon stimulation with viral RNA mimic poly(I:C). By using RNAi and overexpression strategies, we also show key roles in IFNL4 gene expression for the virus-inducible TFs, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), IFN regulatory factor 3 (IRF3), and IRF7. Interestingly, we also observe that overexpression of IFNλ4 influences IFNL4 promoter activity, which may further be dependent on the retinoic acid-inducible gene-I (RIG-I)-like receptor pathway. Together, our work for the first time reports on the functional characterization of the human IFNL4 promoter.
    Preview · Article · Dec 2015 · Viral immunology
    • "Although both are able to induce antiproliferative responses in many cell types, IFN-í µí¼†1 appears to be more limited. Signalling via the IFN-í µí¼†1 results in activation of STATs, MAPKs and PI3K pathways [48] [49] [50]. However, the ability of IFN-í µí¼†1 to trigger these alternative pathways could be cell-type specific or altered in cancer cells. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The overall survival of patients with pancreatic ductal adenocarcinoma is extremely low. Although gemcitabine is the standard used chemotherapy for this disease, clinical outcomes do not reflect significant improvements, not even when combined with adjuvant treatments. There is an urgent need for prognosis markers to be found. The aim of this study was to analyze the potential value of serum cytokines to find a profile that can predict the clinical outcome in patients with pancreatic cancer and to establish a practical prognosis index that significantly predicts patients’ outcomes. We have conducted an extensive analysis of serum prognosis biomarkers using an antibody array comprising 507 human cytokines. Overall survival was estimated using the Kaplan-Meier method. Univariate and multivariate Cox’s proportional hazard models were used to analyze prognosis factors. To determine the extent that survival could be predicted based on this index, we used the leave-one-out cross-validation model. The multivariate model showed a better performance and it could represent a novel panel of serum cytokines that correlates to poor prognosis in pancreatic cancer. B7-1/CD80, EG-VEGF/PK1, IL-29, NRG1-beta1/HRG1-beta1, and PD-ECGF expressions portend a poor prognosis for patients with pancreatic cancer and these cytokines could represent novel therapeutic targets for this disease.
    No preview · Article · Jan 2015 · BioMed Research International
  • Source
    • "Viral infection can induce expression of the type III IFNs in a variety of cell types (Kotenko and others 2003; Sheppard and others 2003). These cytokines signal through a heterodimeric receptor complex consisting of IFN-lR1, the ligand-binding chain, and IL-10R2, the accessory chain (Kotenko and others 2003; Sheppard and others 2003; Donnelly and Kotenko 2010). IFNs induce antiviral activity in cells that express the corresponding cell surface receptors, and IFN-lR1 expression is largely restricted to cells of epithelial origin (Sommereyns and others 2008; Mordstein and others 2010). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The innate immune system must coordinate elaborate signaling pathways to turn on expression of hundreds of genes to provide protection against pathogens and resolve acute inflammation. Multiple genes within distinct functional categories are coordinately and temporally regulated by transcriptional on and off switches in response to distinct external stimuli. Three classes of transcription factors act together with transcriptional coregulators and chromatin-modifying complexes to control these programs. In addition, newer studies implicate long noncoding RNA (lncRNA) as additional regulators of these responses. LncRNAs promote, fine-tune, and restrain the inflammatory program. In this study, we provide an overview of gene regulation and the emerging importance of lncRNAs in the immune system.
    Preview · Article · Sep 2014 · Journal of Interferon & Cytokine Research
Show more

Similar Publications